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ABSTRACT
A Physiologically-Based Pharmacokinetic Model for the Antibiotic Levofloxacin
by
Paezha McCartt
Levofloxacin is in a class of antibiotics known as fluoroquinolones, which treat in-
fections by killing the bacteria that cause them. A physiologically-based pharma-
cokinetic (PBPK) model was developed to investigate the uptake, distribution, and
elimination of Levofloxacin after a single dose. PBPK modeling uses parameters such
as body weight, blood flow rates, partition coefficients, organ volumes, and several
other parameters in order to model the distribution of a particular drug through-
out the body. Levofloxacin is only moderately bound in human blood plasma, and,
thus, for the purposes of this paper, linear bonding is incorporated into the model
because the free or unbound portion of the drug is the only portion that is considered
to be medicinally effective. Parameter estimation is then used to estimate the two
unknown parameters given clinical data from literature on the total concentration
of Levofloxacin in the blood over time. Once an adequate model is generated, the
effects of varying Body Mass Index are tested for the absorption and distribution of
Levofloxacin throughout the body.
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1 Introduction
As described in Reference [19], pharmacokinetics is the study of the effect the
body has on drugs. This branch of science focuses on answering the questions of how
a particular drug enters the body, where the drug goes once it is inside the body, and
how the body gets rid of the drug. Associated with the study of pharmacokinetics is
the acronym ADME. The ‘A’ stands for absorption, the ‘D’ stands for distribution,
the ‘M’ stands for metabolism, and the ‘E’ stands for excretion. Thus, the acronym
ADME lists the different phases a drug goes through when being administered to an
individual. The absorption of a drug is how the drug enters the body. There are
various methods for how a particular drug enters the body. These methods include
oral administration, intravenous administration, intraperitoneal administration, in-
tramuscular administration, and inhalation administration. The most common route
for drug administration is the oral method. Again, the ‘D’ in ADME stands for dis-
tribution, which is where the drug goes in the body once it has been administered
to a patient. This includes how a particular drug is distributed throughout the body
and what portion of the drug is considered to be bound or unbound. The ‘M’ stands
for metabolism. Metabolism is how the body chemically modifies a particular drug.
This process often takes place in the liver but can occur elsewhere, such as the lungs
or gut. There are different enzymes that metabolize different drugs. For instance,
the enzyme Cytochrome 1A2 metabolizes caffeine, and the enzyme Cytochrome E1
metabolizes alcohol. These enzymes metabolize these drugs in a variety of processes.
These processes are oxidation, hydrolysis, and hydroxylation. The ‘E’ in ADME
stands for excretion, which is the irreversible removal of a particular drug from the
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body. Most drugs are excreted by the kidney through the urine, but drugs can also
be excreted in the feces through the hepatic-biliary-liver system or in the sweat [19].
Physiologically-based pharmacokinetic (PBPK) modeling is a type of model-
ing that examines and predicts the absorption, distribution, metabolism, and excre-
tion of a particular drug through the use of mathematical models. In order to use
PBPK modeling, compartments that will be used in the model for the particular drug
must be established. The common compartments used among various different types
of drugs for PBPK modeling are the blood, kidney, gut, fat or adipose tissue, other
tissues, metabolism, urine, and feces [19]. The compartments that should be used in
the PBPK model for a drug are dependent upon the effects the drug has on various
organs and tissues, how it is administrated and excreted, and what one is hoping to
model. To better explain, take for instance the drug ertapenem. As explained in
Reference [7], this drug is administered intravenously, or through the blood, and then
distributed to various organs throughout the body. As a result, blood must be one
of the compartments used in the model for this particular drug. Another aspect of
the drug that must be taken into consideration when creating a model for a partic-
ular drug is determining what an individual is hoping to find out about the drug.
For example, again using the drug ertapenem, one could hope to discover the effect
that body mass index (BMI) has on the distribution of the drug as done by Whitney
Forbes in her thesis [7]. Because BMI deals with adipose tissue or fat, this compart-
ment must be a part of the model as this is what is being studied. The method of
excretion for a particular drug must also be taken into account when creating the
PBPK model. Again using ertapenem, it is metabolized in the kidney and gut and
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then excreted in the urine and feces respectively. Thus, the kidney and gut must also
be compartments in the PBPK model [7]. Since these are the compartments needed
for this particular study, all other tissues are then lumped together in a compartment
labeled other tissues. Again, the compartments are established for a particular drug
based on which organs the drug affects the most, how the drug is administered and
excreted, and what one is hoping to study. These are the basics behind the develop-
ment of the PBPK model. The mathematics involved in the model will be explained
in the following sections.
Once the compartments have been established, how the drug is broken down
or activated must be taken into account. This is a key step in determining the
mathematical equations. To begin, one must examine the different portions of the
drug, specifically the bound and unbound concentrations of the drug. The bound
concentration of the drug is the portion of the drug that stays in the blood until it
is released in a linear or non-linear way. The unbound, or free, concentration of the
drug is the portion of the drug that is considered to be medicinally effective [7].
For the purposes of this paper, PBPK modeling will be used to examine the
drug Levofloxacin. Levofloxacin is in a class of antibiotics known as fluoroquinolones,
which treat infections by killing the bacteria that cause them [13]. Levofloxacin
was approved for use in the United States in 1996 [4]. The chemical structure of
Levofloxacin is shown in Figure 1 below [14]. This particular drug can be used for
a variety of purposes with regards to different types of infections. These various
types of infections include pneumonia, chronic bronchitis, skin infections, urinary
tract infections, sinus infections, prostate infections, and kidney infections [13]. As
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explained in Reference [6], this particular drug can also be used to prevent anthrax
infections for individuals who have been exposed to its germs in the air. The length
of time this particular drug is taken is dependent upon the type and severity of
the infection. However, no matter the length of time, it is important to finish the
prescription and not simply stop taking the antibiotic when an individual believes he
or she is better [5, 21]. In the following sections, we will derive the PBPK model for
Levofloxacin.
Figure 1: Levofloxacin Chemical Structure [14]
2 Model
For the purposes of this paper, we assume Levofloxacin is administered intravenously,
which means it goes directly to into the bloodstream. From the blood stream, the
drug is then distributed throughout the body and enters the various compartments
representing portions on the body. The overall goal of the research conducted on
Levofloxacin is to see how the drug is effected by body mass index, BMI. Therefore,
compartments were chosen in which the effect of altering the BMI could be seen. The
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compartments for our PBPK model of Levofloxacin will be the blood, adipose tissue
(fat), the gut, the kidney, and other tissues, which consists of the rest of the body.
The blood compartment was chosen for the model because the drug is administered
intravenously, which is directly into the blood stream. The adipose compartment
was chosen because the effects of BMI on the distribution of the drug will be ex-
amined. The kidney and gut were chosen due to the fact that they represent the
routes of excretion for Levofloxacin. Lastly, the other tissues compartment because it
encompasses all of the other tissues. After the drug travels through a particular com-
partment, it returns to the blood stream, and the process is repeated. Levofloxacin
is administered daily, and, thus a 24 hour period is used in our model, with the dose
for Levofloxacin being 750 mg [9]. The schematic for our model is given in Figure 2
below.
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Infusion
Blood
Adipose (Fat)
Kidney
Urine
Gut
Feces
Other Tissues
Figure 2: Schematic Representation of the Compartment Model [7]
The rate of infusion for a particular drug is the rate at which the drug is ad-
ministered. Thus, for Levofloxacin, the rate of infusion, denoted RI , is given by the
following:
RI =

0 if t > 1.5
D
1.5
if 0 < t < 1.5.
. (1)
Levofloxacin is administered over a 90 minute period. In the above equation, t > 1.5
stands for when the time exceeds 90 minutes, as t = 1 is one hour and, thus, t = 1.5
is 90 minutes [5]. When the time exceeds 90 minutes, the drug is no longer being
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administered. Thus, the rate of infusion is 0. When the time is less than 90 minutes,
the rate of infusion is D
TI
, where D is the dosage of 750 mg and TI is the length of
time for the infusion.
For each drug, there is a free or unbound concentration in the blood and a bound
concentration of the drug in the blood [7]. The total concentration of the drug in the
blood can then be given by the following equation:
CBl = CBf + CBound,
where CBl, CBf , and CBound stand for the total concentration of the drug in the blood,
the free concentration of the drug in the blood, and the bound concentration of the
drug in the blood, respectively.
Levofloxacin has been found to range from 24-38% bound; therefore, it is only
moderately bound to serum proteins [4]. It is important to remember why it is that
the free portion of the drug must be calculated. The free or unbound portion of a
particular drug is the part of the drug that is medicinally effective as it saturates the
tissues and can be excreted [8]. The bound portion remains in the blood bound to the
plasma [7]. Levofloxacin is 24-38% bound, so, for the purposes of this paper, when
finding an equation for the bound portion of the drug, we will use an approximate
percentage of 30%. Hence, the equation for the bound concentration of the drug is
CBound = 0.30 ∗ CBl.
In order to rewrite the equation for the total concentration of the drug in the
blood, the above equation can be substituted for the bound concentration of the
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blood to produce the following equation
CBl = CBf + 0.30 ∗ CBl.
If the above equation for the total concentration is then manipulated to solve for
the free concentration, we have the following:
CBf = CBl − 0.30 ∗ CBl = 0.70 ∗ CBl. (2)
In order to calculate the the concentration of the drug in each compartment, the
volumes of the various compartments must also be calculated. We assume all of
the subjects were male with the average measurements for height (BH) and weight
(BW ). The values used for the BH and BW are assumed to be 1.75 meters and
72 kilograms, respectively [20]. The subjects’ height and weight were then used to
calculate the volumes of the various compartments used in the model. The equations
for the volumes compartment are given by the following equations:
VBl =
13.1(BH∗100)+18.05(BW )−480
0.5723
VK = 15.4 + 2.04(BW ) + 51.8(BH)
2
VF =
PBF
100
∗
BW
109
0.923
∗ 1000
VG = 0.0171 ∗ (BW ) ∗ 1000,
PBF = 785.58− (563.95 ∗ f(Age))− (27.12 ∗ Sex)−
(1199.65 ∗ f(BMI)) + (461.04 ∗ f(BMI)2) +
(63.08 ∗ f(BMI) ∗ Sex) + (822.11 ∗ f(BMI) ∗ f(Age)−
(25.31 ∗ f(BMI)2 ∗ Sex)− (295.51 ∗ f(BMI)2 ∗ f(Age))
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where VBl, VK , VF , and VG stand for the volume of the blood, volume of the kidney,
volume of the fat, and volume of the gut, respectively. The equations for VBl and
VK were found in reference [18], the equation for VG was found in reference [16], and
the equations for VF and PBF were found in reference [15]. Here, it is important to
note that PBF stands for percent body fat, which is used to find the volume of the
fat compartment as shown in the above equations. For the purposes of this paper,
the sex = 0, indicating a male, and the age = 40, indicating 40 years of age. The
volume of the other tissues compartment is calculated by taking a fraction of the
total body weight that is not included in the other compartments, i.e. the blood,
adipose, kidney, or gut. Thus, an equation for the body weight (BW ) must be found.
According to the International Life Sciences Institute [10], the density of most soft
tissues falls between 0.95 and 1.05. There are only a few tissues with densities outside
the range from 0.9 to 1.1. Thus, in order to formulate an equation for BW , it must
first be assumed that the total volume of the body is equal to the body weight. In
order to change the units for BW , the following equation can be used:
BW = V olume ∗ 1kg
1L
∗ 1L
103mL
[7].
Thus, as stated above, the equation for the volume of the other tissues compartment
(VOT ) can now be constructed:
VOT = BW ∗ 1000− (VBl + VF + VK + VG).
Another important aspect of the mathematical model is the flow rate, denoted
Q. It is of the utmost importance as the rate at which the drug flows through the
various compartments in the body must be known in order to make the model work.
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The total flow rate in the body can be calculated using the body weight (BW ). The
equation for the total flow rate in the body is the following:
QTotal = 235 ∗ (BW )0.71 ∗ 60.
Because the compartments are a percentage of the total body, it is also true that
the flow rates for the various compartments are percentages of the flow rate for the
total body. The different flow rates for the various compartments are listed in Table
1, which were found in References [2] and [16]:
Table 1: Flow Rates
Parameter Value Reference
QTotal 235 ∗ (BW )0.71 ∗ 60 [2]
QF 0.052 ∗QTotal [16]
QK 0.19 ∗QTotal [16]
QG 0.17 ∗QTotal [16]
QOT QTotal − (QF + QK + QG) [16]
Note that, in Table 1, QOT is defined as a fraction of QTotal that is not in the
adipose, kidney, or gut compartments. For the purposes of this paper, the venous-
equilibrium model was used for the various tissue compartments. Through this model,
one is able to conclude that the drug is able to reach an equilibrium concentration
between the tissue and the blood in the amount of time it takes the blood to perfuse
the tissue [7]. From this, one is able to then conclude that the concentration of
Levofloxacin leaving the compartment in the venous blood is at equilibrium with the
concentration of Levofloxacin in the compartment. Thus, a partition coefficient for
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the equilibrium in the various tissues muse be introduced. This equilibrium partition
coefficient will be represented as Pi, where i represents the various tissues represented
by the compartments.
Various partition coefficients are needed for this mathematical model to work
and be successful. The partition coefficients in the model represent the tissue’s sol-
ubility. These coefficients are then able to let one know the percentage of the con-
centration of the drug that can flow from the various tissue compartments back to
the blood. To better understand exactly what the partition coefficients stand for and
their importance, consider the following example: If the partition coefficient for the
kidney is PK = 1.5135, then 1mL of kidney tissue can hold 1.5135 times as much
Levofloxacin as 1mL of blood [7]. “The partition coefficients vary for each drug, and,
thus, were calculated using an algorithm first introduced by Poulin and Krishman,”
[17]. This algorithm uses partition coefficient data that is based on n-octanol:water.
The equation used in the algorithm uses both drug specific and physiological param-
eters to produce the following equation for the partition coefficient of the various
tissues:
Pi =
[So ∗Nt] + [(Sw ∗ 0.7Pt) + So ∗ 0.3Pt)] + [Sw ∗Wt]
[So ∗Nb] + [(Sw ∗ 0.7Pb) + So ∗ 0.3Pb)] + [Sw ∗Wb] .
In the above equation, So and Sw are the solubility of the drug in n-octanol and water,
respectively. Next, Pt,Wt, and Nt are the fractions of the tissue’s volume that are
phospholipids, water, and neutral lipids, respectively. On the other hand, Pb,Wb, and
Nb are the fractions of the blood volume that are phospholipids, water, and neutral
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lipids, respectively. The So and Sw values are drug specific, and, thus, had to be
found in literature. For Levofloxacin, Sw = 1.44mol/m
3 [1]. The So values was not
available, and, thus, had to be calculated using the following equation:
So = Kow ∗ Sw.
In this equation, Kow is the octanol-water partition coefficient. It is also important to
note that logP is equivalent to the Kow, as the logP value is what is reported in the
literature [11]. It was found that logP = Kow = 4.3 [22]. In this algorithm, the parti-
tion coefficient for the other tissues compartment was calculated as the muscle:blood
partition coefficient. The following partition coefficients for the various compartments
were calculated through the algorithm mentioned above and are listed in Table 2.
Table 2: Partition Coefficients
Parameter Value
PF 4.96
PK 1.16
PG 0.91
POT 1.12
A set of differential equations representing the change in concentration of the drug
in each compartment over time (dCtissue
dt
) was constructed. This set of differential
equations is referred to as the ODE System and is given in Equation (3).
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VF
dCF
dt
= QF (CBf − CFPF )
VK
dCK
dt
= QK(CBf − CKPK )− kUCK
VG
dCG
dt
= QG(CBf − CGPG )− kFCG
VOT
dCOT
dt
= QOT (CBf − COTPOT ) (3)
VOT
dCOT
dt
= QOT (CBf − COTPOT )
VBl
dCBl
dt
= QFC
CF
PF
+ QK
CK
PK
+ QG
CG
PG
+ QOT
COT
POT
−QTotalCBf + RI
dAU
dt
= kUCK
dAF
dt
= kFCG
In the above equations, CBf and RI are given in Equations (2) and (1), respectively.
We assume that prior to infusion, there were no traces of Levofloxacin in the body.
Thus, all initial conditions for the model are zero. A summary of variables and
parameters for the model is given in Table 3 below.
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Table 3: Definitions of Model Variables and Parameters
Symbol Description Units
Ci Concentration of Levofloxacin in tissue i mcg/mL
CBf Concentration of free Levofloxacin in the blood i mcg/mL
AU Amount of Levofloxacin in urine mcg
AF Amount of Levofloxacin in feces mcg
Vi Volume of tissue i mL
Qi Flow Rate in tissue i mL/hr
t Time hr
Pi Blood partition coefficient of tissue i dimensionless
BW Body Weight kg
BH Body Height m
RI Rate of Infusion mcg/hr
D Dose mcg
TI Length of Infusion hr
kU First-order rate constant of urine excretion mL/hr
kF First-order rate constant of feces excretion mL/hr
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3 Parameter Estimation
There are two unknown parameters, kU (first-order rate constant of urine excretion)
and kF (first-order rate constant of feces excretion), which are estimated in this
section. For Levofloxacin, clinical data was found for the total concentration of the
drug in the blood at corresponding time points. This data was then extracted using
an extraction program in Matlab, known as GRABIT, which extracts data from a file
image [3]. The clinical data found in Reference [12] is given in Table 4:
Table 4: Clinical Data for the Total Concentration of Levofloxacin [12]
Time (tj) Total Concentration (CBl(tj) ≡ yj)
(hr) (mcg/mL)
1.07 8.44
1.64 11.28
2.16 8.19
3.15 7.07
4.06 6.47
5.14 5.75
6.14 5.29
8.04 4.40
12.03 3.02
24.02 1.04
30.01 0.46
36.01 0.28
It important to note that the data given in Reference [12] is based on 36 hours since
the time of infusion, even though we are primarily analyzing the total concentration
of the drug over a 24 hour time period because Levofloxacin is administered once
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a day. However, in hopes of obtaining more accurate results, all of the data points
given in the literature were implemented into our program in Matlab.
The goal of parameter estimation is to find parameter values for the unknown
parameters such that the model is a good approximation of the measured concentra-
tions in the blood and the measured excretion. Both the data in Table 4 and the fact
that 80 percent of Levofloxacin is excreted in the urine within a 24-hour period are
used to estimate kU and kF . In order to estimate these values, an inverse problem
was implemented. In the inverse problem, J is our cost function,
J(q) =
N∑
j=1
(
yˆ1j − CBl(t,q)
CBl(t,q)
)2
+
(
0.8− AU(24, q)
AU(24, q)
)2
. (4)
For a specific value of kU and kF , the cost function calculates the difference be-
tween both the blood concentrations and urine excretions given by our model versus
the data. These are then summed up for the values at each time step. The goal is
to minimize this function in order to match the model output with the data found in
literature as closely as possible using a program called fminsearch, which is a Matlab
built in program. The function fminsearch uses a Nelder-Mead algorithm to choose
new parameter values based on the calculated value of J. Once a certain criteria is
met, the program outputs the optimal values for the parameters, which in this case
are kU and kF . These values can then be used in the model. Once the cost function
is minimized, one is able to assert that the model output matches the clinical data as
closely as possible.
23
4 Results
After parameter estimation, the results are ready to be analyzed. Figure 3 below
illustrates our model for the total concentration of the drug in the blood over a 24
hour period. We are interested in how our blood concentration levels match up to
the data. We are also interested in our urine excretion with regards to it matching
the data listed in Table 2.
Figure 3: Total Concentration
From the graph, one can the see that the peak point for the clinical data and our
model data match up fairly well. The ending values for the total concentration from
our model data also matches up fairly well with the ending values for the clinical
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data. The final concentrations of the graph are of concern because this is the area in
which the minimum inhibitory concentration level becomes important. The minimum
inhibitory concentration (MIC) level is the level at which, if the concentration of the
drug in the blood falls below this level, the patient becomes susceptible to developing
antibiotic resistance [7].The area under the curve is also of concern as it indicates
the effectiveness of the antibiotic. If the area under the concentration curve is too
high or the peak is too high, then the patient may be susceptible to experiencing
toxic side effects [7]. Thus, the MIC level is important to both know and monitor.
Each antibiotic has a MIC level, which differs depending on the bacteria that the
antibiotic is trying to kill. Hence, when analyzing the results, the data that would be
associated with the MIC level is the area that many are concerned with. The main
issue in matching the clinical data to our model data lies in the middle portion of
the graph. While one might not be as concerned with this portion of the graph as
they are with the end portion of the graph that deals with the MIC level, it is still
important to match the data as closely as possible for more accurate results. When
calculating the partition coefficients, it was observed that altering these coefficients
led to quite significant changes in the model and graph. After further research, it
was found that the equations used to calculate the various partition coefficients offer
a great starting place; however, further analyzing and manipulating these values may
fix the middle portion of the graph. The algorithm used to predict these parameters
may not produce results as accurate as those needed for the model to fairly accurately
mimic the clinical data. It becomes even more evident that the issue lies in the middle
portion of the graph when looking at Table 3, which shows the relative error between
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the clinical data and the model data. From this, one is able to see that there is quite a
bit of difference in the clinical data and the model data, which again, means, further
manipulations, calculations, and reformulations need to be conducted.
Table 5: Comparison between Data and Model for Total Concentration
Clinical Data (mcg/mL) Model Data (mcg/mL) Relative Error (%)
5.44 6.92 27.24
8.44 10.75 27.27
11.28 10.04 11.02
8.19 8.52 4.07
7.07 6.62 6.40
6.47 5.45 15.65
5.75 4.50 21.68
5.29 3.89 26.40
4.40 3.11 29.22
3.02 2.17 28.12
1.04 0.85 18.06
0.46 0.53 16.12
0.28 0.34 18.73
We are also interested in the urine excretion. The clinical data and our model
data match very well as seen in Figure 4. The urine excretion for the clinical date is
80% and the urine excretion for the model is 80.21%. Thus, for the urine excretion,
the data matches up very nice. The percent relative error in point estimates for the
urine is 0.2680%.
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Figure 4: Urine Excretion
Using the inverse problem discussed in the parameter estimation section, we were
able to find the following values for kU and kF :
kU = 1.2924 ml/hr and kF = 0.1160 mL/hr.
These were the optimal values for kU and kF that were used to generate the above
graph for total concentration.
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5 Sensitivity Analysis and Revised Inverse Problem
After obtaining the results of the parameter estimation and looking at the total
concentration graph, it was concluded that a sensitivity analysis should be conducted
in order to obtain better results. There was some doubt surrounding the equation for
calculating the partition coefficients, and, thus we decided to conduct a sensitivity
analysis to test the effects of the partition coefficients. A sensitivity analysis is used to
see how the variables change with respect to the parameters. It allows us to see which
parameters most affect the given variables, and, thus, which parameters need to be
the most precise. In other words, the sensitivity analysis was done in order to see if
the partition coefficient had an effect on the output generated through our model. In
order to do this, a system of differential equations was generated by taking the partial
derivative of the variables with respect to the parameters. The ODE system used for
the sensitivity analysis consisted of 49 differential equations. The partial derivatives
of the original 10 equations that were used in our original ODE system for our PBPK
model where taken with respect to kU , kF , PF , PK , PG, and POT . Instead of listing
all 49 equations here, one set of partial differential equations will be discussed, i.e.
the equations with respect to PF . Recall, PF is the partition coefficient for the fat
compartment. Again, the original equations were are given in Equation (3). Those
equations with respect to PF are as follows:
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d
dt
dAU
dPF
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dCK
dPF
d
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dAF
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= kF
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In order to determine which parameter has the greatest effect on the variables,
we calculated the relative sensitivity in the usual manner by using the modified L2
norm, which is the following:
∣∣∣∣∣∣∣∣∂Ctissue∂qj
∣∣∣∣∣∣∣∣
2
=
[
1
tf − t0
∫ tf
t0
(
∂Ctissue
∂qj
)2
dt
] 1
2
qj
maxCtissue
.
This equation allows us to normalize the sensitivity. The results of the given sensi-
tivity analysis are indicated in Figure 5.
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Figure 5: Sensitivity Analysis Results
From the above graph, we are able to easily conclude that the partition coefficients
have an effect on the model across the board. For this reason, it is easily concluded
that the partition coefficients do need to be accurate in order for our model to fit the
data.
After concluding that the partition coefficients do have an effect on the model,
a revised inverse problem was used to find the optimal values for kU , kF , PF , PK , PG,
and POT . In order to do this, we conducted a revised inverse problem. Again, we used
fminsearch to estimate the values for kU , kF , PF , PK , PG, and POT . In other words,
we now choose q = [kU , kF , PF , PK , PG, POT ] in Equation (4).
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The following table shows the old partition coefficients used in the previous inverse
problem and the new ones generated through the revised inverse problem.
Table 6: Old vs New Partition Coefficients
Old New
PF = 4.96 PF = 1.04
PK = 1.16 PK = 3.03
PG = 0.91 PG = 1.00
POT = 1.12 POT = 1.65
The first model using the original partition coefficients is given in Figure 3. The
second model using the optimal values for the partition coefficients is given in Figure
6.
Figure 6: Model with New Partition Coefficients
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Thus, it can be concluded that the new values found for the partition coefficients
through the revised inverse problem generate a much better model that fits the data.
6 BMI Variation Study
It was speculated that Body Mass Index (BMI) would have an effect on the
distribution of the drug throughout the body. Using our model, we were able to test
the distribution of Levofloxacin throughout the body in individuals who are considered
under weight, normal weight, over weight, obese, and extremely obese. In order to
do this, it is first important to know the calculation for BMI.
BMI =
BW
(BH)2
where BW is measured in kilograms and BM is meters. Using this equation, we were
able to test the affects of varying BMI on the distribution of Levofloxacin throughout
the body. So, in order to do this, we fixed the body height at 177.8 centimeters, which
is equivalent to 5 feet and 9 inches. We were then able to vary the body weight by
setting of values for BMI that were indicative of a particular BMI category. Table 7
lists the ranges for the values of a 5′9” individual given different body weights.
Using the different ranges for BMI for the different categories, we were able to vary
the BW within these ranges in order to see the distribution of the drug throughout
the body.
For individuals who are underweight, concerning the distribution of Lev-
ofloxacin throughout the body, it was concluded that there was less of the drug
in the fat and more in the blood initially as seen in Figure 7. This was expected as an
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Table 7: BMI Ranges for Different BW
Body Type BMI Range
Under Weight under 18.5
Normal Weight 18.5 - 24.9
Over Weight 25 - 29.9
Obesity 30 - 39.9
Extreme Obesity 40 and over
individual who is underweight will have less body fat to store the drug. Because of
this, we see an initial peek in our model that is above the model for an individual of
normal weight. At the end of the model, the levels of Levofloxacin for an individual
who is underweight fell below the levels of an individual of normal weight. Again,
this was expected as Levofloxacin is in the body for a shorter amount of time and is
flowing out faster as a result of there being less fat in the body.
Figure 7: Total Excretion for Underweight Individual
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Figure 8: Data and Model in Figure 7 is shown from 18 to 36 hours
The explanation given for the variance in the model for an individual who is
underweight versus an individual who is of normal weight is shown in the above
figures. The dark blue line is the model for an individual of normal weight that is
simply being used for comparison. Figure 8 zooms in on the final concentrations of
Figure 7. The trend seen at the end of the dosage may be problematic, because it
may cause the concentration to stay below the MIC level for longer than desired,
which could potentially lead to the development of resistant bacteria.
For individuals who are considered overweight, it was concluded that there was
more of the drug in the fat and less in the blood initially as seen in Figure 9. This
was expected as an individual who is overweight will have more body fat to store the
drug. Because of this, we will not see an initial peek in our new model that is above
the original model for an individual of normal weight. At the end of the model, the
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levels of Levofloxacin for an individual who is overweight lie above the levels of an
individual of normal weight. Again, this was expected as Levofloxacin is in the body
for a longer amount of time and is flowing out slower as a result of there being more
fat in the body. The results for total concentration of Levofloxacin in the blood for
an individual who is considered to be overweight are given in Figure 9.
Figure 9: Total Excretion for Overweight Individual
For individuals who are considered to be obese and severely obese, the above
explanation for an individual who is overweight can be used. However, the amount of
fat in the body increases, and, thus, initially the body will have more fat to store the
drug, so, the initial peek in the graph will continue to drop. Again, because of the
increasing amount of fat in the body, the drug will flow out slower, and, thus, we see
the levels at the end of the graph being below those for an individual of normal weight.
The graphs for individuals who are obese or severely obese are given in Figures 10
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and 11, respectively.
Figure 10: Total Excretion for Obese Individual
Figure 11: Total Excretion for Severely Obese Individual
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7 Conclusions
The goal of this research was to develop a mathematical model to analyze the absorp-
tion and distribution of Levofloxacin throughout the body. In the initial model only
values of kU and kF were estimated; however, estimating kU , kF and the partition
coefficients produced a model with a better fit to the data. Using the new model, we
were then able to test the effects of BMI on the distribution of the drug throughout
the body. It was concluded that for individuals with a lower BMI who are considered
underweight, there is an initial peek in the graph above the model for normal BMI
due to the fact that there was initially more of Levofloxacin in the blood, because
there was less fat to store the drug. Towards the end of the 36 hour period, the
levels of Levofloxacin in the blood were below those for an individual with normal
BMI because less of the drug was being stored in the fat, so it was flowing out faster.
The opposite effects were seen in individuals who were overweight, obese, and severely
obese, with the effects increasing as BMI increased. All in all, the model development
proved to be very successful in showing how Levofloxacin is absorbed and distributed
throughout the body and in testing the effects that BMI has on the distribution of
the drug.
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